Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. COVID-19 (Maternity)
  6. Covid-19 Care of pregnant women with suspected PE QEUH, Obstetrics (832)
Announcements and latest updates

Welcome to the Right Decision Service (RDS) newsletter for August 2024.

  1. Contingency planning for RDS outages

Following the recent RDS outages, Tactuum and the RDS team have been reviewing the learning from these incidents. We are committed to doing all we can to ensure a positive outcome by strengthening the RDS to make it fully robust and clinically resilient for the future.

We would like to invite you to a webinar on 26th September 3-4 pm on national and local contingency planning for future RDS outages.  Tactuum and the RDS team will speak about our business continuity plans and the national contingency arrangements we are putting in place. This will also be a space to share local contingency plans, ideas and existing good practice. We would also like to gather your views on who we should send communications to in the event of future outages.

I have sent a meeting request for this date to all editors – please accept or decline to indicate attendance, and please forward on to relevant contacts. You can also contact Olivia.graham@nhs.scot directly to register your interest in participating.

 

2.National  IV fluid prescribing  calculator

This UK CA marked calculator is now live at https://righdecisions.scot.nhs.uk/ivfluids  . It has been developed by a multiprofessional steering group of leads in IV fluids management, as part of the wider Modernising Patient Pathways Programme within the Centre for Sustainable Delivery.  It aims to address a known cause of clinical error in hospital settings, and we hope it will be especially useful to the new junior doctors who started in August.

Please do spread the word about this new calculator and get in touch with any questions.

 

  1. New toolkits

The following toolkits are now live;

  1. Updated guidance on current and future Medical Device Regulations

We have updated and simplified this guidance within our standard operating procedures. We have clarified the guidance on how to determine whether an RDS tool is a medical device, and have provided an interactive powerpoint slideset to steer you through the process.

 

  1. Guide to six stages of RDS toolkit development

We have developed a guide to support editors and toolkit leads through the process of scoping, designing, delivering, quality assuring and implementing a new RDS toolkit.  We hope this will help in project planning and in building shared understanding of responsibilities throughout the full development process.  The guide emphasises that the project does not end with launch of the new toolkit. Implementation, communication and evaluation are ongoing activities throughout the lifetime of the toolkit.

 

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:
  • Thursday 5 September 1-2 pm
  • Wednesday 24 September 4-5 pm
  • Friday 27 September 12-1 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

7 Evaluation projects

Dr Stephen Biggart from NHS Lothian has kindly shared with us the results of a recent survey of use of the Edinburgh Royal Infirmary of Edinburgh Anaesthesia toolkit. This shows that the majority of consultants are using it weekly or monthly, mainly to access clinical protocols, with a secondary purpose being education and training purposes. They tend to find information by navigating by specialty rather than keyword searching, and had some useful recommendations for future development, such as access to quick reference guidance.

We’d really appreciate you sharing any other local evaluations of RDS in this way – it all helps to build the evidence base for impact.

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

 

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

Covid-19 Care of pregnant women with suspected PE QEUH, Obstetrics (832)

Warning
Please report any inaccuracies or issues with this guideline using our online form

1. Principles of care

  • Venous thromboembolism (VTE) is uncommon in pregnancy and the puerperium, but remains a leading cause of maternal death in well-resourced countries.
  • Pregnant women with suspected pulmonary embolus (PE) should be anticoagulated using therapeutic doses of low molecular weight heparin (LMWH) and diagnostic testing undertaken to confirm or exclude the diagnosis.
  • During the COVID-19 pandemic, clinically stable patients should, whenever possible, undergo treatment and investigation on an out-patient basis.
  • Patient safety should not be compromised by any changes to the current guidance.

QEUH Quick Points:

  1. General

Healthboard policy is that pregnant women with ?COVID, and no obstetric complications, presenting to the QEUH site will be triaged to the Specialist Assessment Triage Area (SATA)If admission is required this will be to the medical side.  A document detailing the requirements for obstetric input and review of inpatients on the medical side has already been circulated.

Healthboard policy is that pregnant women with ?COVID, who have obstetric complications, will be triaged to the maternity assessment unit (MAU) .

  1. Specific to suspected pulmonary embolism

The Trakcare request for VQ scan must be done by the reviewing consultant.

When the patient is deemed suitable for outpatient management the organisation of this becomes the remit of the obstetric team – irrespective of which specialty performed the inital review.

Coordination of outpatient arrangements and follow-up requires close communication between MAU and the on-call obstetric team.

2. Initial contact: COVID-19 NOT SUSPECTED

Patients with symptoms of (PE) and NO suspicion of COVID-19 infection, may present at QEUH to the physicians (IAU – Immediate Assessment Unit) or maternity triage depending on the original route of referral.  It has been agreed with nuclear medicine by both specialties on the QEUH site that the Trakcare request for VQ scan has to be made by a consultant.  Irrespective of which specialty performs the initial assessment of the patient, when outpatient management is deemed appropriate this will be facilitated by the obstetric team.

All women who are clinically unstable should be regarded as a medical emergency and have their investigations and treatment undertaken in the Immediate Assessment Unit, QEUH, as happens currently.

3. Initial investigations: COVID-19 NOT SUSPECTED

The initial investigation of women with suspected VTE in pregnancy or the puerperium (including blood tests, clinical observations and chest x-ray) is described on Staffnet guidance.

The woman should be reviewed by the on call Consultant who will determine whether therapeutic doses of LMWH and further imaging are required.

4. Ongoing care: COVID-19 NOT SUSPECTED

If PE is considered a potential diagnosis following consultant review, therapeutic doses of LMWH should be commenced immediately and continued. If the woman lives locally (NHS GG&C) and is clinically stable, she can return home with a supply of LMWH and needle disposal equipment.

A V/Q scan should be requested by the on call Consultant (physician or obstetrician depending on place of initial assessment) and ideally be undertaken as soon as possible (preferably no later than 72 hours after presentation) to prevent a false negative result. Staff contact numbers must be included on the request including the obstetric registrar page number (17111) and the midwife station in MAU (extension 64363/64377).

Women reviewed in IAU (ie by physicians) will be notified to the on-call obstetric registrar or consultant and the obstetric team will take over the outpatient arrangements.  The Trakcare VQ request will have been made by the IAU team.

The on call obstetric team should contact the Nuclear Medicine (NM) Technologist (QEUH) on 0141 452 3669 (Monday to Friday, 9am until 4.30pm) to arrange a time for the scan, and this should be conveyed to the woman along with directions to access the NM Department. The date of the scan should be recorded on a board in MAU.  On a day that an outpatient VQ scan is taking place MAU must liaise with the obstetric on-call team to ensure follow up of the result.

The woman should report to the NM department at the appointment time using her own transport. A provisional scan report will be given by the Clinical Scientist and a formal report issued later that day by the Radiologist.

It is crucially important that the on call team is aware that an out-patient V/Q scan is being undertaken and it is their responsibility to chase-up and act on the result.

  • if the provisional report is negative, the woman can go home and discontinue her LMWH therapy. Once the formal report is available, she will receive a telephone call from the on call obstetric team (registrar or Consultant) to discuss her results and symptoms.
  • If the provisional report is positive, the woman can go home to continue her LMWH therapy. Once the formal report is available, she will receive a telephone call from the on call obstetric team to discuss her results and to arrange a follow up appointment at the obstetric haematology clinic.

5. Initial contact: COVID-19 ALSO SUSPECTED

COVID-19 should be suspected when the patient has a new persistent cough and/or a fever (note a new, continuous cough means coughing for longer than an hour, or three or more coughing episodes in 24 hours. If the patient usually has a cough, it may be worse than usual).Patients with symptoms of PE who also have suspected COVID-19 infection, and have no obstetric complications, will be directed to attend SATA as per GG&C guidelines.  Women with ?PE plus ?COVID and obstetric complications should attend MAU, QEUH.  Guidance is in place regarding the use of PPE in this area.

Consultant review is required to determine whether testing should be undertaken for COVID-19 and whether therapeutic doses of LMWH are required.

The initial ‘routine’ investigations of women with suspected VTE in pregnancy or the puerperium should be performed, including clinical observations and blood tests and CXR

6. Ongoing care: COVID-19 ALSO SUSPECTED

If PE is considered a potential diagnosis following consultant review, therapeutic doses of LMWH should be commenced immediately and continued. If the woman lives locally (NHS GG&C) and is clinically stable, she can return home with a supply of LMWH and needle disposal equipment, and await the result of the COVID-19 test.

If the COVID-19 test is positive and PE is still suspected, the Consultant should discuss further imaging, CTPA, with the Radiology Department at QEUH.

If the COVID-19 test is negative, a V/Q scan should be requested by the on call Consultant and ongoing care undertaken as outlined in section 4.

Editorial Information

Last reviewed: 26/03/2020

Next review date: 21/09/2022

Version: 3

Document Id: 832